Partnerships | Investments | PAIR Technology
In March 2025, Sen-Jam Pharmaceutical hosted a pivotal webinar in collaboration with Destum Partners, a premier strategic advisory firm known for driving success in biotech partnerships, licensing, and M&A. This exclusive session offered investors and industry insiders a rare look behind the curtain—where scientific innovation meets commercial strategy. With several of our leading assets entering Phase 2 clinical milestones and patent protections expanding globally, the timing of this conversation could not have been more crucial. Together with Destum, we outlined our roadmap for unlocking value through co-development and licensing agreements, showcasing how our pipeline aligns with current market opportunities in public health, respiratory infection, addiction recovery, and next-gen anti-inflammatories.
Whether you’re a seasoned investor, a potential partner, or simply intrigued by the future of proactive medicine, this webinar delivers essential context on why Sen-Jam’s platform is poised to reshape the pharmaceutical landscape. It’s a chance to hear directly from our executive leadership—CEO Jim Iversen and Chief Clinical Officer Jackie Iversen—alongside the Destum team, as they unpack the differentiators behind our PAIR (Pleiotropic Anti-Inflammatory Regulators) technology and discuss the unique positioning of assets like SJP-001 and SJP-002C. Don’t miss this opportunity to better understand the momentum building behind Sen-Jam’s innovation engine and the value-creation strategies guiding our next phase of growth.
👉 Watch the full webinar here: Sen-Jam x Destum Partners Strategic Update
